Related Experiment Video
Updated: Apr 15, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Genotyping of mucosal melanoma
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Abstract:
Mucosal melanoma is rare and associated with extremely poor prognosis. Mucosal melanoma has historically been refractory to traditional therapeutic approaches. Recently molecularly based targeted drugs show great success in melanoma. The success of these drug strategies can be partially attributed to the identification of the genetic alterations responsible for the development and progression of metastatic melanoma. This review will focus on genes involved in two major mucosal melanoma-related signaling pathways, the RAS/RAF/mitogen activated protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinases (PI3K)-AKT pathway, and detail the current understanding of their roles in melanoma progression. Additional mutations in key genes, such as KIT, GNAQ and MITF, in mucosal melanoma will also be introduced. Finally, an overview of the current targeted therapy landscape will be provided.
Insights
Mucosal melanoma, a rare cancer, is difficult to treat. This review explores targeted therapies by examining key genes and signaling pathways like RAS/RAF/MAPK and PI3K-AKT involved in melanoma progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mucosal melanoma is a rare cancer with a poor prognosis, historically resistant to conventional treatments.
- Recent advances in targeted therapies have shown success in melanoma, driven by identifying genetic alterations.
- Understanding these genetic drivers is crucial for developing effective treatments.
Purpose of the Study:
- To review genes involved in major signaling pathways in mucosal melanoma.
- To detail the roles of the RAS/RAF/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinases (PI3K)-AKT pathways in melanoma progression.
- To introduce mutations in KIT, GNAQ, and MITF and provide an overview of current targeted therapies.
Main Methods:
- Literature review focusing on genetic alterations in mucosal melanoma.
- Analysis of signaling pathways including RAS/RAF/MAPK and PI3K-AKT.
- Discussion of mutations in KIT, GNAQ, and MITF.
Main Results:
- Identified key genes and signaling pathways implicated in mucosal melanoma development and progression.
- Detailed the functional roles of RAS/RAF/MAPK and PI3K-AKT pathways.
- Highlighted additional significant mutations like KIT, GNAQ, and MITF.
Conclusions:
- Targeted therapies hold promise for treating mucosal melanoma.
- Understanding specific genetic mutations and pathways is essential for advancing treatment strategies.
- Further research into targeted drug development is warranted for this rare cancer.
